Overview

Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

Status:
Active, not recruiting

Trial end date:
2025-12-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using triptorelin, exemestane, and tamoxifen may fight breast cancer by blocking the use of estrogen. It is not yet known whether giving triptorelin together with exemestane is more effective than triptorelin and tamoxifen in treating hormone-responsive breast cancer. PURPOSE: This randomized phase III trial is studying triptorelin and exemestane to see how well they work compared to triptorelin and tamoxifen in treating premenopausal women with hormone-responsive breast cancer.

Phase:

Phase 3

Details

Lead Sponsor:

International Breast Cancer Study Group

Collaborators:

Breast International Group
National Cancer Institute (NCI)

Treatments:

Exemestane
Tamoxifen
Triptorelin Pamoate